Suppr超能文献

结直肠癌患者根治性手术后开始辅助化疗的最佳时间。

Optimal time of initiating adjuvant chemotherapy after curative surgery in colorectal cancer patients.

作者信息

Kang Kyu Min, Hong Kyung Sook, Noh Gyoung Tae, Oh Bo-Young, Chung Soon Sup, Lee Ryung-Ah, Kim Kwang Ho

机构信息

Department of Surgery, Ewha Womans University School of Medicine, Seoul, Korea.

出版信息

Ann Coloproctol. 2013 Aug;29(4):150-4. doi: 10.3393/ac.2013.29.4.150. Epub 2013 Aug 29.

Abstract

PURPOSE

Adjuvant chemotherapy is routinely recommended for locally advanced colorectal cancer (CRC). There are very few data for the optimal starting date of adjuvant chemotherapy after the surgery. This study aimed to evaluate the effectiveness of earlier adoption of adjuvant chemotherapy after curative surgery for stage III CRC.

METHODS

In this study, 159 patients with stage III CRC, who had undergone a curative resection, were enrolled retrospectively. Patients were categorized into 3 groups representing different timings to initiate the chemotherapy; less than 2 weeks (group 1), 3 to 4 weeks (group 2), and more than 5 weeks (group 3). The overall survival rate (OS) and the relapse-free survival rate (RFS) were analyzed to evaluate the effectiveness of adjuvant chemotherapy.

RESULTS

The 5-year OSs of the patients were 73.7% in group 1, 67.0% in group 2, and 55.2% in group 3. The 5-year RFSs of the patients were 48.8% in group 1, 64.7% in group 2, and 57.1% in group 3. There were no significant differences in either the OS or the RFS (P = 0.200, P = 0.405).

CONCLUSION

Starting chemotherapy earlier than 6 weeks after surgery does not show any significant difference. Thus, although adjuvant chemotherapy should preferably begin within 6 weeks, the starting date should not necessarily be hastened, and the patient's general condition should be taken into consideration.

摘要

目的

辅助化疗通常被推荐用于局部晚期结直肠癌(CRC)。关于手术后辅助化疗的最佳起始日期的数据非常少。本研究旨在评估III期CRC根治性手术后尽早采用辅助化疗的有效性。

方法

在本研究中,回顾性纳入了159例接受了根治性切除的III期CRC患者。患者被分为3组,代表开始化疗的不同时间;少于2周(第1组)、3至4周(第2组)和超过5周(第3组)。分析总生存率(OS)和无复发生存率(RFS)以评估辅助化疗的有效性。

结果

第1组患者的5年总生存率为73.7%,第2组为67.0%,第3组为55.2%。第1组患者的5年无复发生存率为48.8%,第2组为64.7%,第3组为57.1%。总生存率和无复发生存率均无显著差异(P = 0.200,P = 0.405)。

结论

术后6周内更早开始化疗未显示出任何显著差异。因此,虽然辅助化疗最好在6周内开始,但不一定非要提前起始日期,应考虑患者的一般状况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb85/3767864/3032397dc918/ac-29-150-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验